Genprex reports positive preclinical data for GPX-002 using lipid nanoparticle delivery at ADA 2025

Genprex, Inc.

Nine LNPs tested; two were highly efficient in transfecting α- and β-cells in isolated mouse islets.
LNP using ALX-184 with mRNA payload injected into mouse common bile duct efficiently transfected pancreatic cells.
Non-viral LNP approach could enable repeat dosing and may eliminate need for immunosuppression.
Research presented at ADA 85th Scientific Sessions in Chicago; builds on ongoing AAV-based studies.
Company views results as proof-of-concept for a next-generation diabetes gene therapy delivery system.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.